Algernon Pharmaceuticals completes name change to Algernon Health

Algernon Pharmaceuticals (AGNPF) completed its previously announced name change to Algernon Health. The Company’s common shares will begin trading under the new name on the CSE at market-open on Monday, October 20, 2025. The common shares will trade under the new name with a new CUSIP number, but the stock symbol will remain the same. In connection with the name change, the following new CUSIP and ISIN numbers have been assigned to the common shares of the Company. No action is required to be taken by the shareholders with respect to the name change. This name changeover on the Company’s website, in its digital marketing and social media materials and links, and in its URL and company email addresses will be changed on a rolling basis over a short window of time, as files and platforms are updated and refreshed across various networks and platforms. The name change reflects the Company’s recent announcement that it will be focusing on the Alzheimer’s Disease diagnostic market with plans to establish specialized neuroimaging clinics across North America as its lead program. The clinics will feature the latest technology of U.S. FDA-cleared, optimized brain-specific Positron Emission Tomography scanning systems to detect amyloid plaques in patients, providing significantly lower radiation compared to standard PET/CT machines currently in operation globally. The PET scans are covered by Medicare, Medicaid, and private insurance.